RTP Mobile Logo
Select Publications

Abida W et al. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses. ESMO 2019;Abstract 846PD.

André F et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019;380(20):1929-40. Abstract

Barrett MT et al. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Br J Cancer 2017;117(4):572-82. Abstract

Bastos DA, Antonarakis ES. Darolutamide for castration-resistant prostate cancer. Onco Targets Ther 2019;12:8769-77. Abstract

Bodor JN et al. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer 2020;126(2):260-70. Abstract

Bonanno L et al. Clinical impact of plasma and tissue next-generation sequencing in advanced non-small cell lung cancer: A real-world experience. The Oncologist 2020;[Online ahead of print]. Abstract

Chang S et al. Current status and future perspectives of liquid biopsy in non-small cell lung cancer. J Pathol Transl Med 2020;54(3):204-12. Abstract

Chowdhury S et al. Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC). ESMO 2018;Abstract 795PD.

Dawson SJ et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368(13):1199-209. Abstract

Dustin D et al. ESR1 mutations in breast cancer. Cancer 2019;125(21):3714-28. Abstract

Esagian SM et al. Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: A comprehensive systematic review. J Cancer Res Clin Oncol 2020;146(8):2051-66. Abstract

Fribbens C et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 2016;34(25):2961-8. Abstract

Girolami I et al. Programmed Death-Ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papillary thyroid carcinoma: A systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma. Endocr Pathol 2020;[Online ahead of print]. Abstract

Hussain M et al. PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. ESMO 2019;Abstract LBA12_PR.

Kneuertz PJ et al. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma. Lung Cancer 2020;143:60-6. Abstract

Lagos GG et al. Beyond tumor PD-L1: Emerging genomic biomarkers for checkpoint inhibitor immunotherapy. Am Soc Clin Oncol Educ Book 2020;40:1-11. Abstract

Laha D et al. New therapies for advanced thyroid cancer. Front Endocrinol (Lausanne) 2020;11:82. Abstract

Lan X et al. Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis. Cancer Sci 2020;111(6):2163-73. Abstract

Lantuejoul S et al. PD-L1 testing for lung cancer in 2019: Perspective from the IASLC Pathology Committee. J Thorac Oncol 2020;15(4):499-519. Abstract

Mack PC et al. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases. Cancer 2020;126(14):3219-28. Abstract

Makarem M, Leighl NB. Molecular testing for lung adenocarcinoma: Is it time to adopt a "plasma-first" approach? Cancer 2020;126(14):3176-80. Abstract

Marmarelis ME, Langer CJ. Treatment of patients with non-small-cell lung cancer harboring rare oncogenic mutations. Clin Lung Cancer 2020;21(5):395-406. Abstract

McKenzie A et al. Adoption and utilization of NGS-based molecular profiling in community-based oncology practices: Insights from Sarah Cannon. ASCO 2019;Abstract e18064.

Middleton G et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature 2020;[Online ahead of print]. Abstract

Rajurkar S et al. Non-small cell lung cancer from genomics to therapeutics: A framework for community practice integration to arrive at personalized therapy strategies. J Clin Med 2020;9(6):E1870. Abstract

Rossi G et al. Precision medicine for NSCLC in the era of immunotherapy: New biomarkers to select the most suitable treatment or the most suitable patient. Cancers (Basel) 2020;12(5):1125. Abstract

Sands JM et al. Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung Cancer 2020;140:35-41. Abstract

Salgia R et al. Evaluation of omics-based strategies for the management of advanced lung cancer. JCO Oncol Pract 2020;[Online ahead of print]. Abstract

Sears CR, Mazzone PJ. Biomarkers in lung cancer. Clin Chest Med 2020;41(1):115-27. Abstract

Sholl LM et al. The promises and challenges of tumor mutation burden as an immunotherapy biomarker: A perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol 2020;[Online ahead of print]. Abstract

Singh B et al. Molecular profiling for malignancies: Knowledge gaps and variable practice patterns among United States oncologists. ASCO 2019;Abstract 10510.

Solomon JP et al. NTRK fusion detection across multiple assays and 33,997 cases: Diagnostic implications and pitfalls. Mod Pathol 2020;33(1):38-46. Abstract

Taniguchi H et al. Targeted therapies and biomarkers in small cell lung cancer. Front Oncol 2020;10:741. Abstract

Tran TV et al. Evaluation of the expression levels of BRAF(V600E) mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay. BMC Cancer 2020;20(1):368. Abstract

Willis J et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin Cancer Res 2019;25(23):7035-45. Abstract

Xiao Q et al. Serum biomarkers for thyroid cancer. Biomark Med 2020;[Online ahead of print]. Abstract

Zhen DB et al. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. Semin Oncol 2018;45(3):107-15. Abstract